<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227042</url>
  </required_header>
  <id_info>
    <org_study_id>250-902</org_study_id>
    <nct_id>NCT03227042</nct_id>
  </id_info>
  <brief_title>A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)</brief_title>
  <official_title>A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a natural history study for children up to 18 years of age who have been diagnosed
      with Mucopolysaccharidosis Type IIIB (MPS IIIB, also known as Sanfilippo Syndrome Type B).
      Mucopolysaccharidosis type IIIB is a severe neurodegenerative disorder. The information
      gathered from this trial may help inform the design and interpretation of subsequent
      interventional studies. No clinical intervention or study drug is provided by BioMarin in
      this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">November 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>Baseline + every 24 weeks for up to 192 weeks</time_frame>
    <description>A neurodevelopmental assessment will be performed using standardized developmental tests to provide quantifiable measures of neurocognitive function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral function</measure>
    <time_frame>Baseline + every 24 weeks for up to 192 weeks</time_frame>
    <description>Disease-related behaviors will be assessed using an MPS IIIB specific behavior rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Tests</measure>
    <time_frame>Baseline + every 24 weeks for up to 192 weeks</time_frame>
    <description>Multiple QoL tools will be used to capture physical, mental, and social well-being of the patient as well as to examine the impact of the patient's disease on the parent/guardian and family.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep habits</measure>
    <time_frame>Baseline + every 24 weeks for up to 192 weeks</time_frame>
    <description>Patient sleep habits will be assessed using Children's Sleep Habits Questionnaires (CSHQ).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-specific Biomarkers</measure>
    <time_frame>Baseline + every 24 weeks for up to 192 weeks</time_frame>
    <description>Urine sample for glycosaminoglycans (GAGs) and creatinine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical, Molecular, Cellular and Genetic Markers of Disease Burden</measure>
    <time_frame>Once (at baseline visit)</time_frame>
    <description>Blood and urine samples will be used to evaluate biochemical, molecular cellular, and genetic/genomic aspects of MPS IIIB.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mucopolysaccharidosis Type IIIB</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Males and Females with a documented diagnosis of MPSIIIB
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have deficient NAGLU enzyme activity at Baseline. Blood for NAGLU enzyme activity will
             be collected and analyzed centrally.

          -  Is up to 18 years of age

          -  Written informed consent from parent or legal guardian and assent from subject, if
             required

          -  Has the ability to comply with protocol requirements, in the opinion of the
             investigator

        Exclusion Criteria:

          -  Has another neurological illness that may have caused cognitive decline (e.g., trauma,
             meningitis, or hemorrhage) before study entry

          -  Has received stem cell, gene therapy, or enzyme replacement therapy for MPS IIIB

          -  Has received any investigational medication within 30 days prior to the Baseline visit
             or is scheduled to receive any investigational drug during the course of the study

          -  Has a medical condition or extenuating circumstance that, in the opinion of the
             investigator, might compromise the subject's ability to comply with protocol
             requirements, the subject's wellbeing or safety, or the interpretability of the
             subject's clinical data.

          -  Is currently participating in another natural history study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BioMarin Trial Inquiries</last_name>
    <phone>1-800-983-4587</phone>
    <email>medinfo@bmrn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Luc</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>4785</phone_ext>
      <email>cluc@mail.cho.org</email>
    </contact>
    <investigator>
      <last_name>Paul Harmatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute and Royal Children's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Kokoszka</last_name>
      <phone>+61 3 9936 6157</phone>
      <email>shannon.kokoszka@rch.org.au</email>
    </contact>
    <investigator>
      <last_name>Heidi Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Genetics Service/HCPA, Department of Genetics/UFRGS</name>
      <address>
        <city>Pôrto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa Da Silva</last_name>
      <phone>+55 51 3359 6366</phone>
      <email>laposilva@hcpa.edu.br</email>
    </contact>
    <investigator>
      <last_name>Roberto Giugliani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Lippold</last_name>
      <phone>49-40-7410-53710</phone>
      <email>m.lippold@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Julia Voelker</last_name>
      <phone>00</phone>
      <email>j.voelker@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nicole Muschol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María José De Castro</last_name>
      <phone>+34.698.18.64.38</phone>
      <email>mj.decastrol@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Luz Couce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Children's Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youhsin Huang</last_name>
      <phone>+886-2-25433535</phone>
      <phone_ext>3089</phone_ext>
      <email>mmhrdchuang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Shuan-Pei Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gazi University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mine Tutkal</last_name>
      <phone>+90 505 253 86 34</phone>
      <email>minetutkal.74@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ilyas Okur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sanfilippo Syndrome Type B</keyword>
  <keyword>MPS IIIB</keyword>
  <keyword>MPS 3 B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis III</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

